GlaxoSmithKline Pharmaceuticals Limited Cash Flow Conversion Efficiency

Latest as of September 2023: 0.024x

GlaxoSmithKline Pharmaceuticals Limited cash flow conversion efficiency. Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has a cash flow conversion efficiency ratio of 0.024x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs362.20 Million ≈ $3.92 Million USD) by net assets (Rs15.40 Billion ≈ $166.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of GlaxoSmithKline Pharmaceuticals Limited (2005–2025)

Cash flow conversion efficiency of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025. This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GLAXO stock price for real-time trading data and today's change.

GlaxoSmithKline Pharmaceuticals Limited Cash Flow Conversion Ratio Explained

GlaxoSmithKline Pharmaceuticals Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

GlaxoSmithKline Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GlaxoSmithKline Pharmaceuticals Limited ranked by their cash flow conversion efficiency. Also see market cap of GlaxoSmithKline Pharmaceuticals Limited for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Amentum Holdings Inc. NYSE:AMTM	0.030x
Spirit Aerosystems Holdings Inc NYSE:SPR	0.041x
Travere Therapeutics Inc NASDAQ:TVTX	2.368x
Mercury Systems Inc NASDAQ:MRCY	0.033x
Exchange Income Corporation TO:EIF	0.112x
Applied Digital Corporation NASDAQ:APLD	0.038x
Iridium Communications Inc NASDAQ:IRDM	0.242x
TFS Financial Corporation NASDAQ:TFSL	0.017x

Annual Cash Flow Conversion Efficiency for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)

The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025. Review how much free cash does GlaxoSmithKline Pharmaceuticals Limited generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	Rs19.51 Billion ≈ $211.03 Million	Rs12.90 Billion ≈ $139.50 Million	0.661x	+101.90%
2024-03-31	Rs17.78 Billion ≈ $192.24 Million	Rs5.82 Billion ≈ $62.94 Million	0.327x	+17.74%
2023-03-31	Rs17.41 Billion ≈ $188.31 Million	Rs4.84 Billion ≈ $52.37 Million	0.278x	-8.66%
2022-03-31	Rs26.63 Billion ≈ $287.99 Million	Rs8.11 Billion ≈ $87.68 Million	0.304x	-21.03%
2021-03-31	Rs14.99 Billion ≈ $162.12 Million	Rs5.78 Billion ≈ $62.50 Million	0.386x	+43.09%
2020-03-31	Rs18.21 Billion ≈ $196.89 Million	Rs4.90 Billion ≈ $53.05 Million	0.269x	+44.35%
2019-03-31	Rs21.40 Billion ≈ $231.41 Million	Rs3.99 Billion ≈ $43.19 Million	0.187x	-18.79%
2018-03-31	Rs20.57 Billion ≈ $222.49 Million	Rs4.73 Billion ≈ $51.13 Million	0.230x	+95.43%
2017-03-31	Rs20.07 Billion ≈ $217.03 Million	Rs2.36 Billion ≈ $25.52 Million	0.118x	+43.29%
2016-03-31	Rs16.96 Billion ≈ $183.42 Million	Rs1.39 Billion ≈ $15.05 Million	0.082x	-25.74%
2015-03-31	Rs24.44 Billion ≈ $264.32 Million	Rs2.70 Billion ≈ $29.21 Million	0.111x	-21.83%
2014-03-31	Rs19.90 Billion ≈ $215.18 Million	Rs2.81 Billion ≈ $30.42 Million	0.141x	-9.52%
2013-03-31	Rs20.07 Billion ≈ $217.03 Million	Rs3.14 Billion ≈ $33.91 Million	0.156x	-9.88%
2012-03-31	Rs19.36 Billion ≈ $209.34 Million	Rs3.36 Billion ≈ $36.30 Million	0.173x	-29.41%
2011-03-31	Rs19.52 Billion ≈ $211.06 Million	Rs4.79 Billion ≈ $51.84 Million	0.246x	-14.23%
2010-03-31	Rs17.86 Billion ≈ $193.16 Million	Rs5.12 Billion ≈ $55.32 Million	0.286x	+36.72%
2009-03-31	Rs15.76 Billion ≈ $170.39 Million	Rs3.30 Billion ≈ $35.69 Million	0.209x	-9.28%
2008-03-31	Rs13.81 Billion ≈ $149.33 Million	Rs3.19 Billion ≈ $34.48 Million	0.231x	+7.57%
2007-03-31	Rs12.05 Billion ≈ $130.29 Million	Rs2.59 Billion ≈ $27.97 Million	0.215x	-41.44%
2006-03-31	Rs9.53 Billion ≈ $103.08 Million	Rs3.49 Billion ≈ $37.78 Million	0.367x	+47.85%
2005-03-31	Rs9.24 Billion ≈ $99.90 Million	Rs2.29 Billion ≈ $24.77 Million	0.248x	--

About GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO India Drug Manufacturers - General

Market Cap

$4.64 Billion

Rs428.83 Billion INR

Market Cap Rank

#3628 Global

#157 in India

Share Price

Rs2531.40

Change (1 day)

+1.49%

52-Week Range

Rs2103.20 - Rs3106.40

All Time High

Rs3466.20